Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 936-942

  Henry, N Lynn ^a   Azzouz, Faouzi ^b   Desta, Zereunesay ^b   Li, Lang ^b   Nguyen, Anne T ^b   Lemler, Suzanne ^b   Hayden, Jill ^a   Tarpinian, Karineh ^d   Yakim, Elizabeth ^d   Flockhart, David A ^b   Stearns, Vered ^d   Hayes, Daniel F ^a   Storniolo, Anna Maria ^c  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; LETROZOLE; TAXANE DERIVATIVE; ANDROSTANE DERIVATIVE; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CARPAL TUNNEL SYNDROME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN TINGLING; TENDINITIS; BREAST TUMOR; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROGNOSIS; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROGNOSIS; PROSPECTIVE STUDIES; TRIAZOLES; WITHHOLDING TREATMENT;

EID: 84860618475     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.0261     Document Type: Article

References (20)

1. Dowsett M, Cuzick J, Ingle J, et al: Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
2. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
3. Goss PE, Ingle JN, Pater JL, et al: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008
4. Goss PE, Ingle JN, Chapman J-AW, et al: Final analysis of NCIC CTG MA.27: A randomized phase III trial of exemestane versus anastrozole in post-menopausal women with hormone receptor positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S1-1)
5. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
6. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
7. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
8. Henry NL, Giles JT, Ang D, et al: Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365-372, 2008
9. Henry NL, Giles JT, Stearns V: Aromatase inhibitor-associated musculoskeletal symptoms: Etiology and strategies for management. Oncology (Williston Park) 22:1401-1408, 2008
10. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883, 2007 (Pubitemid 47477264)
11. Briot K, Tubiana-Hulin M, Bastit L, et al: Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: The ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127-134, 2010
12. Sestak I, Cuzick J, Sapunar F, et al: Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis. Lancet Oncol 9:866-872, 2008
13. Wolfe F, Michaud K, Strand V: Expanding the definition of clinical differences: From minimally clinically important differences to really important differences - Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 32:583-589, 2005 (Pubitemid 40524688)
14. Farrar JT, Pritchett YL, Robinson M, et al: The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: Analyses of data from clinical trials of duloxetine in pain disorders. J Pain 11:109-118, 2009
15. Goss PE, Ingle JN, AleBs-Martínez JE, et al: Exemestane for breast-cancer prevention in post-menopausal women. N Engl J Med 364:2381-2391, 2011
16. Henry NL, Pchejetski D, A'Hern R, et al: Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A casecontrol study. Br J Cancer 103:291-296, 2010
17. Ingle JN, Schaid DJ, Goss PE, et al: Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682, 2010
18. Henry NL, Banerjee M, Wicha M, et al: Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117:5469-5475, 2011
19. Mao JJ, Stricker C, Bruner D, et al: Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631-3639, 2009
20. Buzdar AU: Clinical features of joint symptoms observed in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24:15s, 2006 (suppl 1; abstr 551)